- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 89,860 | 03.06.24 15:45:33 | +0,080 | +0,09% | 89,920 | 89,980 | 88,320 | 89,780 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 909,200 | 03.06.24 14:09:52 | +10,800 | +1,20% | 912,800 | 918,800 | 900,200 | 898,400 |
